Sign in

Michael Sonntag

Senior Equity Research Analyst at Leerink Partners

Michael Sonntag is a Senior Equity Research Analyst at Leerink Partners, specializing in Medical Devices and Technology sectors with deep expertise in immuno-oncology. He covers notable companies such as Affimed N.V., Arcellx, Arcus Biosciences, Viridian Therapeutics, and Xenon Pharmaceuticals, and has been recognized for delivering thorough research and actionable insights to institutional clients. Sonntag began his analyst career at Leerink Partners and continues to expand his coverage across several emerging biopharmaceutical firms. He is FINRA registered and holds relevant securities licenses, reflecting his commitment to professional standards and regulatory compliance.

Michael Sonntag's questions to OABI leadership

Michael Sonntag's questions to OABI leadership • Q2 2025

Question

Michael Sonntag of Leerink Partners inquired about discovery activity trends between large pharma and small biotech, and whether the reiterated 2025 guidance now includes revenue from the new Exploration platform.

Answer

CEO Matthew Foehr noted that program growth is strong across both large pharma and smaller biotech partners. CFO Kurt Gustafson and CEO Matthew Foehr clarified that while guidance is unchanged, revenue from the Exploration platform is considered additive and accretive to the business.

Ask Fintool Equity Research AI